India's Bharti Airtel partners Ericsson 5G Core technology to drive 5G evolution
New agreement spans packet core, signaling, charging & policy solutions STOCKHOLM, Feb. 25, 2025 /PRNewswire/ -- India's Bharti Airtel and Ericsson (NASDAQ: ERIC) have strengthened their longstanding partnership through a new collaboration to...
BioCity Announces its selective Endothelin Type-A Receptor Antagonist, SC0062, Met the Primary Endpoint in Diabetic Kidney Disease (DKD) in a Phase 2 trial (2-SUCCEED)
SHANGHAI, Feb. 23, 2025 /PRNewswire/ -- BioCity Biopharma (BioCity) announced that its selective endothelin receptor type A (ETA) antagonist, SC0062, met the 12-week primary endpoint of a reduction in proteinuria in the diabetic kidney disease (DKD)...
China committed to acting as an 'enabler'
BEIJING, Feb. 25, 2025 /PRNewswire/ -- A report from People's Daily: Recently, a foreign scholar described China as an "enabler." This term vividly encapsulates China's commitment to building a community with a shared future for mankind and...
Kerry Establishes Local Manufacturing Partnership for Taste Solutions in Pakistan
KARACHI, Pakistan, Feb. 25, 2025 /PRNewswire/ -- Kerry, a global leader in taste and nutrition, has partnered with Far Eastern Impex (FEI) to open the first international production operation for flavourings in Pakistan. The manufacturing facility,...
How 51Talk is Redefining Online Education Through AI--from the Boardroom to the Classroom
SINGAPORE, Feb. 25, 2025 /PRNewswire/ -- 51Talk, an online English language education platform, has announced plans to launch a comprehensive, AI-powered systems upgrade across its business operations within the coming months. Partnering with top...
Consensus concludes sold-out debut event in Hong Kong and announces return to Asia in 2026
The Hong Kong Convention and Exhibition Centre reached maximum capacity, with nearly 10,000 in-person attendees from over 100 countries, solidifying the conference's position as a marquee event of the region. The conference, and its 350+ side events...
CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA
Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The GEMSTONE-303 study results support sugemalimab in combination with chemotherapy as a new...
Lessons from Japan's AMR Response for the Global Community
https://iris.who.int/handle/10665/380481 TOKYO, Feb. 25, 2025 /PRNewswire/ -- World Health Organization (WHO) Regional Office for the Western Pacific (WPRO) has released Japan's AMR Response 2013–2025 alongside Tokyo AMR One Health Conference...